2 hours ago
Mike Sharma, MD, MSc, discusses how asundexian’s approval revolutionizes secondary stroke prevention – and may provide a pathway to treat many more conditions.
5 hours ago
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
6 hours ago
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.
7 hours ago
Patricia Bloom, MD, examines microbiome therapies for hepatic encephalopathy, FMT findings, and challenges in HE drug development.
7 hours ago
Patricia Bloom, MD, discusses treatment gaps in hepatic encephalopathy and the role of adjunctive therapies in 2026 ACG guidance.